Matinas Biopharma (NYSEAMERICAN:MTNB) Posts Quarterly Earnings Results

Matinas Biopharma (NYSEAMERICAN:MTNB) issued its quarterly earnings results on Tuesday. The company reported ($0.26) EPS for the quarter, FiscalAI reports.

Matinas Biopharma Stock Performance

NYSEAMERICAN MTNB traded down $0.05 during trading on Thursday, hitting $0.50. 3,239 shares of the company’s stock traded hands, compared to its average volume of 28,209. The business has a 50 day moving average of $0.61 and a 200-day moving average of $0.98. Matinas Biopharma has a 12-month low of $0.47 and a 12-month high of $3.09. The stock has a market capitalization of $3.21 million, a price-to-earnings ratio of -0.25 and a beta of 1.39.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Matinas Biopharma stock. DRW Securities LLC bought a new position in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned approximately 0.72% of Matinas Biopharma at the end of the most recent reporting period. 11.77% of the stock is owned by institutional investors.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.